Cyxone, a biotech company specializing in autoimmune diseases, in collaboration with its CDMO partner, has streamlined part of the manufacturing process for its drug candidate Rabeximod, which is under development for the treatment of rheumatoid arthritis (RA). As part of the continued development of Rabeximod, Cyxone is now, in collaboration with its CDMO, working on the development of creating a scalable manufacturing process for the late development phases as well as the commercialization ...